Low impact
Johnson & Johnson entered a strategic agreement with Sail Biomedicines, involving initial payments of $785 million and an exclusive option to acquire Sail for $2.58 billion.
WSJ07/30, 05:13 AM
Related assets
Coming up for JNJ
Explore next
Latest JNJ news
Finnhub08/27, 12:50 PM
Johnson & Johnson's autoimmune drug received FDA approval for treatment of a rare blood disease.
FirstSquawk08/08, 08:14 AM
Duato sold 41,957 J&J shares at an average price of $258.06.
FirstSquawk08/08, 08:13 AM
J&J's Duato disclosed a share sale of $1.69M at an average price of $258.74.